# VRDN Score Reconciliation — Session 34

**Date**: 2026-04-13
**Issue**: S26 scored VRDN at 26.0 (watchlist demotion) based on REVEAL-1 market reaction. S33 suggested 30.0 based on REVEAL-1 data being "platform de-risking." Which is correct?

## Resolution: S26 IS CORRECT. Score remains 26.0.

### Why S33 Was Wrong

S33 encountered the March 30, 2026 8-K (REVEAL-1 positive topline results) during a PDUFA date verification task. It read the headline data — primary endpoint met, strong responder rates — and interpreted it as incremental positive news for the VRDN franchise. S33 suggested a score of 30.0.

However, S33 did not have context on:
1. **Market expectations**: Investors expected Q4W placebo-adjusted responder rates of 51-73%; REVEAL-1 delivered 36-45%.
2. **The Tepezza benchmark**: Tepezza (teprotumumab, Amgen) achieved 83% responder rate in its pivotal. Elegrobart's 54% Q4W raw rate (36% placebo-adj) does not establish competitive superiority.
3. **The stock reaction**: VRDN crashed -32.3% on Mar 30 (13.8M volume) and another -26.2% on Apr 6 (14.5M volume), cumulative -43.8% from Mar 27 close. This is the definitive market verdict.
4. **Franchise de-rating**: The SC formulation (elegrobart) was supposed to be VRDN's long-term competitive weapon against Tepezza SC. REVEAL-1 showed it's not clearly better, reducing the franchise's long-term value.

S33's error was treating the 8-K as a fresh discovery without checking whether prior sessions had already analyzed the same event. This is a known session-continuity failure mode: each session reads raw data independently but may not cross-reference prior session analysis of the same data.

### Current VRDN Tape

| Date | Close | Cumulative from pre-REVEAL-1 |
|------|-------|------------------------------|
| Mar 27 | $27.39 | baseline |
| Mar 30 | $18.53 | -32.3% (REVEAL-1 readout) |
| Apr 6 | $13.90 | -49.2% (second crash, SC digest) |
| Apr 10 | $14.95 | -45.4% |

Price has stabilized in the $14-15 range over the past 5 trading days (Apr 7-10). Volume declining from 14.5M → 2.4M. This IS genuine stabilization now (unlike the false stabilization S25 called at $15.38 before the Apr 6 crash).

### Score Confirmation: 26.0 (Watchlist)

S26's detailed re-score stands:
- Signal Strength: 3.0 × 2.0 = 6.0
- Catalyst Clarity: 4.5 × 1.0 = 4.5
- Information Asymmetry: 2.0 × 1.5 = 3.0
- Risk/Reward: 2.5 × 1.0 = 2.5
- Edge Decay: 2.0 × 1.0 = 2.0
- Liquidity: 4.0 × 1.0 = 4.0
- Catalyst Timeline: 4.0 × 1.0 = 4.0
- **Total: 26.0 / 42.5**

### Watchlist Monitoring Criteria

Per S26:
- If VRDN rebounds to >$19: re-evaluate (would signal market digestion complete)
- If drops below $12: archive entirely
- Veligrotug PDUFA June 30 remains the next binary catalyst — approval still expected (~75-80% probability based on Priority Review + no AdCom)
- But even on approval, upside is capped by franchise de-rating

### Process Learning

**Add to session continuity rules**: When a scanner or verification task surfaces data from an 8-K or press release, ALWAYS check `working/` folder for prior session analyses of the same event before writing a score recommendation. S33 would have found `session26_vrdn_reveal_impact.md` and avoided the contradiction.

## Decision

VRDN score: **26.0 confirmed** (unchanged from S26). S33's 30.0 suggestion is rejected. Update SESSION_STATE to remove the "reconciliation needed" flag.
